Compare GE Vernova Inc (GEV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? GE Vernova Inc trades at $1,013.51 (market cap $265.56B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: GE Vernova Inc is far larger — about 2.1× Vertex Pharmaceuticals Incorporated's market cap, and GE Vernova Inc pays a 0.2% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GEV | VRTX | |
|---|---|---|
Market Cap | $265.56B | $128.16B |
Volume | 1,805,141 | 806,603 |
Sector | Industrials | Health |
52-Week High | $1.17K | $557.96 |
52-Week Low | $547.96 | $407.37 |
Typical Hold Time | 36 Days | 120 Days |
Enterprise Value | $255.23B | $122.29B |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed estimates. The company benefits from AI-driven power demand growth and secured the first US construction permit for its BWRX-300 small modular reactor.
GEV presents compelling growth potential driven by AI infrastructure demand and nuclear energy expansion, with revenue projected to grow from $38.1B to $41.4B. However, elevated valuation multiples (P/E 28.59, EV/EBITDA 85.02) and execution risks in the wind power segment warrant caution. The strong analyst consensus and 45% YTD gain suggest continued momentum if operational targets are met.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
